Compare HY & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | BBOT |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.9M | 741.1M |
| IPO Year | 2012 | N/A |
| Metric | HY | BBOT |
|---|---|---|
| Price | $40.18 | $8.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 52.3K | ★ 398.2K |
| Earning Date | 05-05-2026 | 05-26-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.41 | $8.08 |
| 52 Week High | $44.55 | $14.87 |
| Indicator | HY | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 44.30 |
| Support Level | $35.37 | $8.08 |
| Resistance Level | $40.25 | $12.36 |
| Average True Range (ATR) | 1.45 | 0.62 |
| MACD | 0.50 | 0.05 |
| Stochastic Oscillator | 98.66 | 43.03 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.